Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Authors:
Jaffer A. Ajani The University of Texas MD Anderson Cancer Center;

Search for other papers by Jaffer A. Ajani in
Current site
Google Scholar
PubMed
Close
 MD
,
Thomas A. D’Amico Duke Cancer Institute;

Search for other papers by Thomas A. D’Amico in
Current site
Google Scholar
PubMed
Close
 MD
,
David J. Bentrem Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

Search for other papers by David J. Bentrem in
Current site
Google Scholar
PubMed
Close
 MD, MS
,
Joseph Chao City of Hope National Medical Center;

Search for other papers by Joseph Chao in
Current site
Google Scholar
PubMed
Close
 MD
,
David Cooke UC Davis Comprehensive Cancer Center;

Search for other papers by David Cooke in
Current site
Google Scholar
PubMed
Close
 MD
,
Carlos Corvera UCSF Helen Diller Family Comprehensive Cancer Center;

Search for other papers by Carlos Corvera in
Current site
Google Scholar
PubMed
Close
 MD
,
Prajnan Das The University of Texas MD Anderson Cancer Center;

Search for other papers by Prajnan Das in
Current site
Google Scholar
PubMed
Close
 MD, MS, MPH
,
Peter C. Enzinger Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center;

Search for other papers by Peter C. Enzinger in
Current site
Google Scholar
PubMed
Close
 MD
,
Thomas Enzler University of Michigan Rogel Cancer Center;

Search for other papers by Thomas Enzler in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Paul Fanta UC San Diego Moores Cancer Center;

Search for other papers by Paul Fanta in
Current site
Google Scholar
PubMed
Close
 MD
,
Farhood Farjah Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

Search for other papers by Farhood Farjah in
Current site
Google Scholar
PubMed
Close
 MD
,
Hans Gerdes Memorial Sloan Kettering Cancer Center;

Search for other papers by Hans Gerdes in
Current site
Google Scholar
PubMed
Close
 MD
,
Michael K. Gibson Vanderbilt-Ingram Cancer Center;

Search for other papers by Michael K. Gibson in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Steven Hochwald Roswell Park Comprehensive Cancer Center;

Search for other papers by Steven Hochwald in
Current site
Google Scholar
PubMed
Close
 MD
,
Wayne L. Hofstetter The University of Texas MD Anderson Cancer Center;

Search for other papers by Wayne L. Hofstetter in
Current site
Google Scholar
PubMed
Close
 MD
,
David H. Ilson Memorial Sloan Kettering Cancer Center;

Search for other papers by David H. Ilson in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Rajesh N. Keswani Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

Search for other papers by Rajesh N. Keswani in
Current site
Google Scholar
PubMed
Close
 MD
,
Sunnie Kim University of Colorado Cancer Center;

Search for other papers by Sunnie Kim in
Current site
Google Scholar
PubMed
Close
 MD
,
Lawrence R. Kleinberg The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

Search for other papers by Lawrence R. Kleinberg in
Current site
Google Scholar
PubMed
Close
 MD
,
Samuel J. Klempner Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center;

Search for other papers by Samuel J. Klempner in
Current site
Google Scholar
PubMed
Close
 MD
,
Jill Lacy Yale Cancer Center/Smilow Cancer Hospital;

Search for other papers by Jill Lacy in
Current site
Google Scholar
PubMed
Close
 MD
,
Quan P. Ly Fred & Pamela Buffett Cancer Center;

Search for other papers by Quan P. Ly in
Current site
Google Scholar
PubMed
Close
 MD
,
Kristina A. Matkowskyj University of Wisconsin Carbone Cancer Center;

Search for other papers by Kristina A. Matkowskyj in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Michael McNamara Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

Search for other papers by Michael McNamara in
Current site
Google Scholar
PubMed
Close
 MD
,
Mary F. Mulcahy Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

Search for other papers by Mary F. Mulcahy in
Current site
Google Scholar
PubMed
Close
 MD
,
Darryl Outlaw O’Neal Comprehensive Cancer Center at UAB;

Search for other papers by Darryl Outlaw in
Current site
Google Scholar
PubMed
Close
 MD
,
Haeseong Park Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

Search for other papers by Haeseong Park in
Current site
Google Scholar
PubMed
Close
 MD, MPH
,
Kyle A. Perry The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

Search for other papers by Kyle A. Perry in
Current site
Google Scholar
PubMed
Close
 MD
,
Jose Pimiento Moffitt Cancer Center;

Search for other papers by Jose Pimiento in
Current site
Google Scholar
PubMed
Close
 MD
,
George A. Poultsides Stanford Cancer Institute;

Search for other papers by George A. Poultsides in
Current site
Google Scholar
PubMed
Close
 MD, MS
,
Scott Reznik UT Southwestern Simmons Comprehensive Cancer Center;

Search for other papers by Scott Reznik in
Current site
Google Scholar
PubMed
Close
 MD
,
Robert E. Roses Abramson Cancer Center at the University of Pennsylvania;

Search for other papers by Robert E. Roses in
Current site
Google Scholar
PubMed
Close
 MD
,
Vivian E. Strong Memorial Sloan Kettering Cancer Center;

Search for other papers by Vivian E. Strong in
Current site
Google Scholar
PubMed
Close
 MD
,
Stacey Su Fox Chase Cancer Center;

Search for other papers by Stacey Su in
Current site
Google Scholar
PubMed
Close
 MD
,
Hanlin L. Wang UCLA Jonsson Comprehensive Cancer Center;

Search for other papers by Hanlin L. Wang in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Georgia Wiesner Vanderbilt-Ingram Cancer Center;

Search for other papers by Georgia Wiesner in
Current site
Google Scholar
PubMed
Close
 MD
,
Christopher G. Willett Duke Cancer Institute;

Search for other papers by Christopher G. Willett in
Current site
Google Scholar
PubMed
Close
 MD
,
Danny Yakoub St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center;

Search for other papers by Danny Yakoub in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Harry Yoon Mayo Clinic Cancer Center;

Search for other papers by Harry Yoon in
Current site
Google Scholar
PubMed
Close
 MD
,
Nicole McMillian National Comprehensive Cancer Network.

Search for other papers by Nicole McMillian in
Current site
Google Scholar
PubMed
Close
 MS
, and
Lenora A. Pluchino National Comprehensive Cancer Network.

Search for other papers by Lenora A. Pluchino in
Current site
Google Scholar
PubMed
Close
 PhD
Restricted access

Gastric cancer is the third leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location and histologic type. Gastric cancer generally carries a poor prognosis because it is often diagnosed at an advanced stage. Systemic therapy can provide palliation, improved survival, and enhanced quality of life in patients with locally advanced or metastatic disease. The implementation of biomarker testing, especially analysis of HER2 status, microsatellite instability (MSI) status, and the expression of programmed death-ligand 1 (PD-L1), has had a significant impact on clinical practice and patient care. Targeted therapies including trastuzumab, nivolumab, and pembrolizumab have produced encouraging results in clinical trials for the treatment of patients with locally advanced or metastatic disease. Palliative management, which may include systemic therapy, chemoradiation, and/or best supportive care, is recommended for all patients with unresectable or metastatic cancer. Multidisciplinary team management is essential for all patients with localized gastric cancer. This selection from the NCCN Guidelines for Gastric Cancer focuses on the management of unresectable locally advanced, recurrent, or metastatic disease.

Individual Disclosures for the NCCN Gastric Cancer Panel
Individual Disclosures for the NCCN Gastric Cancer Panel

  • Collapse
  • Expand
  • 1.

    Sitarz R, Skierucha M, Mielko J, et al. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res 2018;10:239248.

  • 2.

    Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006;12:354362.

  • 3.

    Ma J, Shen H, Kapesa L, et al. Lauren classification and individualized chemotherapy in gastric cancer. Oncol Lett 2016;11:29592964.

  • 4.

    National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Stat Facts: Stomach Cancer. 2021. Accessed July 9, 2021. Available at: https://seer.cancer.gov/statfacts/html/stomach.html

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends-an update. Cancer Epidemiol Biomarkers Prev 2016;25:1627.

  • 6.

    Etemadi A, Safiri S, Sepanlou SG, et al. The global, regional, and national burden of stomach cancer in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease study 2017. Lancet Gastroenterol Hepatol 2020;5:4254.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394424.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    World Health Organization. International Agency for Research on Cancer. GLOBOCAN 2020: stomach cancer fact sheet. 2020. Accessed July 9, 2021. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/7-Stomach-fact-sheet.pdf

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Zhao JK, Wu M, Kim CH, et al. Jiangsu Four Cancers Study: a large case-control study of lung, liver, stomach, and esophageal cancers in Jiangsu Province, China. Eur J Cancer Prev 2017;26:357364.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin 2021;71:733.

  • 11.

    World Health Organization. International Agency for Research on Cancer. GLOBOCAN 2020: United States of America cancer fact sheet. 2020. Accessed July 9, 2021. Available at: http://gco.iarc.fr/today/data/factsheets/populations/840-united-states-of-america-fact-sheets.pdf

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Bergquist JR, Leiting JL, Habermann EB, et al. Early-onset gastric cancer is a distinct disease with worrisome trends and oncogenic features. Surgery 2019;166:547555.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Karimi P, Islami F, Anandasabapathy S, et al. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev 2014;23:700713.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Yusefi AR, Bagheri Lankarani K, Bastani P, et al. Risk factors for gastric cancer: a systematic review. Asian Pac J Cancer Prev 2018;19:591603.

  • 15.

    Hu B, El Hajj N, Sittler S, et al. Gastric cancer: classification, histology and application of molecular pathology. J Gastrointest Oncol 2012;3:251261.

  • 16.

    Tramacere I, Negri E, Pelucchi C, et al. A meta-analysis on alcohol drinking and gastric cancer risk. Ann Oncol 2012;23:2836.

  • 17.

    He Z, Zhao TT, Xu HM, et al. Association between alcohol consumption and the risk of gastric cancer: a meta-analysis of prospective cohort studies. Oncotarget 2017;8:8445984472.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Wang PL, Xiao FT, Gong BC, et al. Alcohol drinking and gastric cancer risk: a meta-analysis of observational studies. Oncotarget 2017;8:9901399023.

  • 19.

    Deng W, Jin L, Zhuo H, et al. Alcohol consumption and risk of stomach cancer: a meta-analysis. Chem Biol Interact 2021;336:109365.

  • 20.

    Falk J, Carstens H, Lundell L, et al. Incidence of carcinoma of the oesophagus and gastric cardia. Changes over time and geographical differences. Acta Oncol 2007;46:10701074.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Powell J, McConkey CC, Gillison EW, et al. Continuing rising trend in oesophageal adenocarcinoma. Int J Cancer 2002;102:422427.

  • 22.

    Amin MB, Edge SB, Greene FL, et al., eds. AJCC cancer staging manual, 8th Ed. New York, NY: Springer; 2017.

  • 23.

    Bando E, Makuuchi R, Irino T, et al. Validation of the prognostic impact of the new tumor-node-metastasis clinical staging in patients with gastric cancer. Gastric Cancer 2019;22:123129.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Sano T, Coit DG, Kim HH, et al. Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project. Gastric Cancer 2017;20:217225.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    In H, Solsky I, Palis B, et al. Validation of the 8th edition of the AJCC TNM staging system for gastric cancer using the National Cancer Database. Ann Surg Oncol 2017;24:36833691.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Huang SF, Chien TH, Fang WL, et al. The 8th edition American Joint Committee on gastric cancer pathological staging classification performs well in a population with high proportion of locally advanced disease. Eur J Surg Oncol 2018;44:16341639.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Abdalla EK, Pisters PWT. Staging and preoperative evaluation of upper gastrointestinal malignancies. Semin Oncol 2004;31:513529.

  • 28.

    Kwee RM, Kwee TC. Imaging in local staging of gastric cancer: a systematic review. J Clin Oncol 2007;25:21072116.

  • 29.

    Weber WA, Ott K. Imaging of esophageal and gastric cancer. Semin Oncol 2004;31:530541.

  • 30.

    Matsumoto Y, Yanai H, Tokiyama H, et al. Endoscopic ultrasonography for diagnosis of submucosal invasion in early gastric cancer. J Gastroenterol 2000;35:326331.

  • 31.

    Cardoso R, Coburn N, Seevaratnam R, et al. A systematic review and meta-analysis of the utility of EUS for preoperative staging for gastric cancer. Gastric Cancer 2012; 15(S1, Suppl 1)S19S26.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Spolverato G, Ejaz A, Kim Y, et al. Use of endoscopic ultrasound in the preoperative staging of gastric cancer: a multi-institutional study of the US gastric cancer collaborative. J Am Coll Surg 2015;220:4856.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Tsendsuren T, Jun S-M, Mian X-H. Usefulness of endoscopic ultrasonography in preoperative TNM staging of gastric cancer. World J Gastroenterol 2006;12:4347.

  • 34.

    Stahl A, Ott K, Weber WA, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 2003;30:288295.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Wieder HA, Krause BJ, Herrmann K. PET and PET-CT in esophageal and gastric cancer. Methods Mol Biol 2011;727:5976.

  • 36.

    Chen J, Cheong J-H, Yun MJ, et al. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer 2005;103:23832390.

  • 37.

    Rosenbaum SJ, Stergar H, Antoch G, et al. Staging and follow-up of gastrointestinal tumors with PET/CT. Abdom Imaging 2006;31:2535.

  • 38.

    Dassen AE, Lips DJ, Hoekstra CJ, et al. FDG-PET has no definite role in preoperative imaging in gastric cancer. Eur J Surg Oncol 2009;35:449455.

  • 39.

    Lim JS, Yun MJ, Kim M-J, et al. CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy. Radiographics 2006;26:143156.

  • 40.

    Sarela AI, Lefkowitz R, Brennan MF, et al. Selection of patients with gastric adenocarcinoma for laparoscopic staging. Am J Surg 2006;191:134138.

  • 41.

    Bentrem D, Wilton A, Mazumdar M, et al. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Ann Surg Oncol 2005;12:347353.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Mezhir JJ, Shah MA, Jacks LM, et al. Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients. Ann Surg Oncol 2010;17:31733180.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    De Andrade JP, Mezhir JJ. The critical role of peritoneal cytology in the staging of gastric cancer: an evidence-based review. J Surg Oncol 2014;110:291297.

  • 44.

    Chau I, Norman AR, Cunningham D, et al. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer─pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 2004;22:23952403.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Karpeh MS, Leon L, Klimstra D, et al. Lymph node staging in gastric cancer: is location more important than number? An analysis of 1,038 patients. Ann Surg 2000;232:362371.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Hechtman JF, Polydorides AD. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. Arch Pathol Lab Med 2012;136:691697.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008;19:15231529.

  • 48.

    Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review. Int J Cancer 2012;130:28452856.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Gómez-Martin C, Garralda E, Echarri MJ, et al. HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer. J Clin Pathol 2012;65:751757.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Jørgensen JT, Hersom M. HER2 as a prognostic marker in gastric cancer - a systematic analysis of data from the literature. J Cancer 2012;3:137144.

  • 51.

    Kato S, Okamura R, Baumgartner JM, et al. Analysis of circulating tumor DNA and clinical correlates in patients with esophageal, gastroesophageal junction, and gastric adenocarcinoma. Clin Cancer Res 2018;24:62486256.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Cho JH, Lim JY, Cho JY. Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer. World J Gastroenterol 2017;23:74077414.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Grabsch H, Sivakumar S, Gray S, et al. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol 2010;32:5765.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Janjigian YY, Werner D, Pauligk C, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA international collaborative analysis. Ann Oncol 2012;23:26562662.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Kunz PL, Mojtahed A, Fisher GA, et al. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol 2012;20:1324.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Tanner M, Hollmén M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005;16:273278.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Yan B, Yau EX, Bte Omar SS, et al. A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol 2010;63:839842.

  • 58.

    Kim WH, Gomez-Izquierdo L, Vilardell F, et al. HER2 status in gastric and gastroesophageal junction cancer: results of the large, multinational HER-EAGLE study. Appl Immunohistochem Mol Morphol 2018;26:239245.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Van Cutsem E, Bang YJ, Feng-Yi F, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 2015;18:476484.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687697.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Bartley AN, Washington MK, Colasacco C, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol 2017;35:446464.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797805.

  • 63.

    Rüschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010;457:299307.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Murphy KM, Zhang S, Geiger T, et al. Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers. J Mol Diagn 2006;8:305311.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357:409413.

  • 66.

    Bartley AN, Fitzgibbons PL, Broaddus RR, et al. Template for reporting results of DNA mismatch repair testing in patients being considered for checkpoint inhibitor immunotherapy. Northfield, IL: College of American Pathologists; 2018.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67.

    Willis J, Lefterova MI, Artyomenko A, et al. Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel. Clin Cancer Res 2019;25:70357045.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Brar SS, Mahar AL, Helyer LK, et al. Processes of care in the multidisciplinary treatment of gastric cancer: results of a RAND/UCLA expert panel. JAMA Surg 2014;149:1825.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    Siewert JR. Carcinoma of the cardia: carcinoma of the gastroesophageal junction classification, pathology, and extent of resection. Dis Esophagus 1996;9:173182.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Rüdiger Siewert J, Feith M, Werner M, et al. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 2000;232:353361.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71.

    MacLeod CM, ed. The clinical evaluation of chemotherapeutic agents in cancer. In: Evaluation of Chemotherapeutic Agents. New York, NY: Columbia University Press; 1949.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649655.

  • 73.

    Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 1984;2:187193.

  • 74.

    Glimelius B, Ekström K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163168.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75.

    Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011;47:23062314.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Kang JH, Lee SI, Lim DH, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012;30:15131518.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Ford HE, Marshall A, Bridgewater JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 2014;15:7886.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78.

    Al-Batran SE, Pauligk C, Homann N, et al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). Eur J Cancer 2013;49:835842.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    Chung HC, Bang YJ, Fuchs CS, et al. First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. Future Oncol 2021;17:491501.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80.

    Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 2021;398:2740.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81.

    Al-Batran S-E, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008;26:14351442.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 82.

    Enzinger PC, Burtness BA, Niedzwiecki D, et al. CALGB 80403 (Alliance)/E1206: a randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers. J Clin Oncol 2016;34:27362742.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 83.

    Kim GM, Jeung HC, Rha SY, et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Eur J Cancer 2012;48:518526.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 84.

    Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2009;20:16671673.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85.

    Bouché O, Raoul JL, Bonnetain F, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. J Clin Oncol 2004;22:43194328.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 86.

    Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20:666673.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 87.

    Louvet C, André T, Tigaud JM, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002;20:45434548.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 88.

    Al-Batran S-E, Atmaca A, Hegewisch-Becker S, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004;22:658663.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 89.

    Park YH, Lee JL, Ryoo BY, et al. Capecitabine in combination with oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer. Cancer Chemother Pharmacol 2008;61:623629.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 90.

    Luo HY, Xu RH, Wang F, et al. Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer. Chemotherapy 2010;56:94100.

  • 91.

    Okines AFC, Norman AR, McCloud P, et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009;20:15291534.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 92.

    Wang G, Yang B, Fu Z, et al. Efficacy and safety of oxaliplatin-based regimen versus cisplatin-based regimen in the treatment of gastric cancer: a meta-analysis of randomized controlled trials. Int J Clin Oncol 2019;24:614623.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 93.

    Hall PS, Swinson D, Waters JS, et al. Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): the GO2 phase III trial. J Clin Oncol 2019;37(15_suppl):4006.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 94.

    Enzinger PC, Kulke MH, Clark JW, et al. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci 2005;50:22182223.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 95.

    Ajani JA, Baker J, Pisters PWT, et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 2002;94:641646.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 96.

    Moehler M, Haas U, Siebler J, et al. Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer. Anticancer Drugs 2003;14:645650.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 97.

    Pozzo C, Barone C, Szanto J, et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol 2004;15:17731781.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 98.

    Moehler M, Eimermacher A, Siebler J, et al. Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer 2005;92:21222128.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 99.

    Beretta E, Di Bartolomeo M, Buzzoni R, et al. Irinotecan, fluorouracil and folinic acid (FOLFIRI) as effective treatment combination for patients with advanced gastric cancer in poor clinical condition. Tumori 2006;92:379383.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 100.

    Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008;19:14501457.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 101.

    Brell JM, Krishnamurthi SS, Javle M, et al. A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma. Cancer Chemother Pharmacol 2009;63:851857.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 102.

    Enzinger PC, Ryan DP, Clark JW, et al. Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer. Ann Oncol 2009;20:475480.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 103.

    Lustberg MB, Bekaii-Saab T, Young D, et al. Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. J Thorac Oncol 2010;5:713718.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 104.

    Moehler M, Kanzler S, Geissler M, et al. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2010;21:7177.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 105.

    Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. J Clin Oncol 2014;32:35203526.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 106.

    Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:49914997.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 107.

    Roth AD, Fazio N, Stupp R, et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 2007;25:32173223.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 108.

    Al-Batran SE, Hartmann JT, Hofheinz R, et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2008;19:18821887.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 109.

    Elsaid AA, Elkerm Y. Final results of a randomized phase III trial of docetaxel, carboplatin and 5FU versus epirubicin, cisplatin and 5FU for locally advanced gastric cancer. J Clin Oncol 2005;23(16_suppl):4014.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 110.

    Inal A, Kaplan MA, Kucukoner M, et al. Docetaxel and cisplatin plus fluorouracil compared with modified docetaxel, cisplatin, and 5-fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution. Neoplasma 2012;59:233236.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 111.

    Di Lauro L, Vici P, Belli F, et al. Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer. Gastric Cancer 2014;17:718724.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 112.

    Van Cutsem E, Boni C, Tabernero J, et al. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Ann Oncol 2015;26:149156.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 113.

    Shah MA, Janjigian YY, Stoller R, et al. Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium. J Clin Oncol 2015;33:38743879.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 114.

    Ilson DH, Forastiere A, Arquette M, et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 2000;6:316323.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 115.

    Petrasch S, Welt A, Reinacher A, et al. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br J Cancer 1998;78:511514.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 116.

    Gadgeel SM, Shields AF, Heilbrun LK, et al. Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. Am J Clin Oncol 2003;26:3741.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 117.

    Ajani JA, Fodor MB, Tjulandin SA, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 2005;23:56605667.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 118.

    Kim JY, Do YR, Park KU, et al. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. Cancer Chemother Pharmacol 2010;66:3136.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 119.

    Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003;21:5459.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 120.

    Hong YS, Song SY, Lee SI, et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol 2004;15:13441347.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 121.

    Albertsson M, Johansson B, Friesland S, et al. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. Med Oncol 2007;24:407412.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 122.

    Ajani JA, Ilson DH, Daugherty K, et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994;86:10861091.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 123.

    Ilson DH, Wadleigh RG, Leichman LP, et al. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol 2007;18:898902.

  • 124.

    Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383:3139.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 125.

    Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014;15:12241235.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 126.

    Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med 2020;382:24192430.

  • 127.

    Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 2013;31:44384444.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 128.

    Fuchs CS, Moore MR, Harker G, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003;21:807814.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 129.

    Sym SJ, Hong J, Park J, et al. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy. Cancer Chemother Pharmacol 2013;71:481488.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 130.

    Maugeri-Saccà M, Pizzuti L, Sergi D, et al. FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort. J Exp Clin Cancer Res 2013;32:67.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 131.

    Sym SJ, Ryu MH, Lee JL, et al. Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane. Am J Clin Oncol 2008;31:151156.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 132.

    Assersohn L, Brown G, Cunningham D, et al. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 2004;15:6469.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 133.

    U.S. Food and Drug Administration. FDA approves Lonsurf for recurrent, metastatic gastric and gastroesophageal junction adenocarcinoma. 2019. Available at: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm632032.htm. Accessed March 6, 2020.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 134.

    Shitara K, Doi T, Dvorkin M, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2018;19:14371448.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 135.

    Ilson DH, Tabernero J, Prokharau A, et al. Efficacy and safety of trifluridine/tipiracil treatment in patients with metastatic gastric cancer who had undergone gastrectomy: subgroup analyses of a randomized clinical trial. JAMA Oncol 2019;6:e193531.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 136.

    Shitara K, Doi T, Hosaka H, et al. Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged ≥65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): subgroup analysis from TAGS. J Clin Oncol 2019;37(15_suppl):4037.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 137.

    Ilson DH. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. Oncology (Williston Park) 2004; 18(14, Suppl 14)2225.

  • 138.

    Sakai D, Boku N, Kodera Y, et al. An intergroup phase III trial of ramucirumab plus irinotecan in third or more line beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial). J Clin Oncol 2018;36(15_suppl):TPS4138.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 139.

    Klempner SJ, Maron SB, Chase L, et al. Initial report of second-line FOLFIRI in combination with ramucirumab in advanced gastroesophageal adenocarcinomas: a multi-institutional retrospective analysis. Oncologist 2019;24:475482.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 140.

    Burtness B, Gibson M, Egleston B, et al. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Ann Oncol 2009;20:12421248.

  • 141.

    Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:25092520.

  • 142.

    Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38:110.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 143.

    Berton D, Banerjee SN, Curigliano G, et al. Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability–high tumors: a combined analysis of two cohorts in the GARNET study. J Clin Oncol 2021;39(15_suppl):2564.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 144.

    Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020;21:13531365.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 145.

    Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020;21:271282.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 146.

    Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731739.

  • 147.

    Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 2018;4:e180013.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 148.

    Le DT, Uram JN, Wang H, et al. PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers. J Clin Oncol 2016;34(4_suppl):195.

  • 149.

    U.S. Food and Drug Administration. FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC. 2019. Accessed July 14, 2020. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 150.

    U.S. Food and Drug Administration. FDA approves larotrectinib for solid tumors with NTRK gene fusions. 2018. Accessed July 14, 2020. Available at: https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 151.

    Rivera F, Romero C, Jimenez-Fonseca P, et al. Phase II study to evaluate the efficacy of trastuzumab in combination with capecitabine and oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial. Cancer Chemother Pharmacol 2019;83:11751181.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 152.

    Soularue É, Cohen R, Tournigand C, et al. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. Bull Cancer 2015;102:324331.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 153.

    Makiyama A, Sukawa Y, Kashiwada T, et al. Randomized, phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT Study). J Clin Oncol 2020;38:19191927.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 154.

    Tabernero J, Ohtsu A, Muro K, et al. Exposure-response analyses of ramucirumab from two randomized, phase III trials of second-line treatment of advanced gastric or gastroesophageal junction cancer. Mol Cancer Ther 2017;16:22152222.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 155.

    Fuchs CS, Shitara K, Di Bartolomeo M, et al. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20:420435.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 156.

    U.S. Food and Drug Administration. FDA approves nivolumab in combination with chemotherapy for metastatic gastric cancer and esophageal adenocarcinoma. 2021. Accessed November 4, 2021. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-combination-chemotherapy-metastatic-gastric-cancer-and-esophageal

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 157.

    U.S. Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. 2017. Accessed February 21, 2020. Available at: https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm560040.htm

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 158.

    U.S. Food and Drug Administration. FDA approves pembrolizumab for adults and children with TMB-H solid tumors. 2020. Accessed January 19, 2021. Available at: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 159.

    U.S. Food and Drug Administration. FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors. 2021. Accessed August 30, 2021. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 160.

    Oaknin A, Tinker AV, Gilbert L, et al. Clinical activity and safety of the anti–programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair–deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol 2020;6:17661772.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 161.

    Gatalica Z, Xiu J, Swensen J, et al. Molecular characterization of cancers with NTRK gene fusions. Mod Pathol 2019;32:147153.

  • 162.

    Okamura R, Boichard A, Kato S, et al. Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics. JCO Precis Oncol 2018;PO.18.00183.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 163.

    Arnold A, Daum S, von Winterfeld M, et al. Analysis of NTRK expression in gastric and esophageal adenocarcinoma (AGE) with pan-TRK immunohistochemistry. Pathol Res Pract 2019;215:152662.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 164.

    Shinozaki-Ushiku A, Ishikawa S, Komura D, et al. The first case of gastric carcinoma with NTRK rearrangement: identification of a novel ATP1B-NTRK1 fusion. Gastric Cancer 2020;23:944947.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 165.

    Imbesi JJ, Kurtz RC. A multidisciplinary approach to gastrointestinal bleeding in cancer patients. J Support Oncol 2005;3:101110.

  • 166.

    Kim YI, Choi IJ. Endoscopic management of tumor bleeding from inoperable gastric cancer. Clin Endosc 2015;48:121127.

  • 167.

    Sheibani S, Kim JJ, Chen B, et al. Natural history of acute upper GI bleeding due to tumours: short-term success and long-term recurrence with or without endoscopic therapy. Aliment Pharmacol Ther 2013;38:144150.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 168.

    Poultsides GA, Kim CJ, Orlando R III, et al. Angiographic embolization for gastroduodenal hemorrhage: safety, efficacy, and predictors of outcome. Arch Surg 2008;143:457461.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 169.

    Kim MM, Rana V, Janjan NA, et al. Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol 2008;47:421427.

  • 170.

    Kondoh C, Shitara K, Nomura M, et al. Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study. BMC Palliat Care 2015;14:37.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 171.

    Jeurnink SM, van Eijck CHJ, Steyerberg EW, et al. Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review. BMC Gastroenterol 2007;7:1827.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 172.

    Lim S, Muhs BE, Marcus SG, et al. Results following resection for stage IV gastric cancer; are better outcomes observed in selected patient subgroups? J Surg Oncol 2007;95:118122.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 173.

    Holt AP, Patel M, Ahmed MM. Palliation of patients with malignant gastroduodenal obstruction with self-expanding metallic stents: the treatment of choice? Gastrointest Endosc 2004;60:10101017.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 174.

    Lindsay JO, Andreyev HJN, Vlavianos P, et al. Self-expanding metal stents for the palliation of malignant gastroduodenal obstruction in patients unsuitable for surgical bypass. Aliment Pharmacol Ther 2004;19:901905.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 175.

    Kim TO, Kang DH, Kim GH, et al. Self-expandable metallic stents for palliation of patients with malignant gastric outlet obstruction caused by stomach cancer. World J Gastroenterol 2007;13:916920.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 176.

    Endo S, Takiguchi S, Miyazaki Y, et al. Efficacy of endoscopic gastroduodenal stenting for gastric outlet obstruction due to unresectable advanced gastric cancer: a prospective multicenter study. J Surg Oncol 2014;109:208212.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 177.

    Ly J, O’Grady G, Mittal A, et al. A systematic review of methods to palliate malignant gastric outlet obstruction. Surg Endosc 2010;24:290297.

  • 178.

    Jeurnink SM, Steyerberg EW, van Hooft JE, et al. Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study): a multicenter randomized trial. Gastrointest Endosc 2010;71:490499.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 179.

    Issaka RB, Shapiro DM, Parikh ND, et al. Palliative venting percutaneous endoscopic gastrostomy tube is safe and effective in patients with malignant obstruction. Surg Endosc 2014;28:16681673.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 180.

    Wollman B, D’Agostino HB. Percutaneous radiologic and endoscopic gastrostomy: a 3-year institutional analysis of procedure performance. AJR Am J Roentgenol 1997;169:15511553.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 181.

    Silas AM, Pearce LF, Lestina LS, et al. Percutaneous radiologic gastrostomy versus percutaneous endoscopic gastrostomy: a comparison of indications, complications and outcomes in 370 patients. Eur J Radiol 2005;56:8490.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 182.

    Lee MJ, Saini S, Brink JA, et al. Malignant small bowel obstruction and ascites: not a contraindication to percutaneous gastrostomy. Clin Radiol 1991;44:332334.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 183.

    Ryan JM, Hahn PF, Mueller PR. Performing radiologic gastrostomy or gastrojejunostomy in patients with malignant ascites. AJR Am J Roentgenol 1998;171:10031006.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 73279 33481 2964
PDF Downloads 58713 27229 2518
EPUB Downloads 0 0 0